Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives $40.82 Consensus Price Target from Brokerages

Capricor Therapeutics, Inc. (NASDAQ:CAPR) has been given a consensus rating of “Moderate Buy” by the ten brokerages that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating and nine have given a buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $40.8182.

A number of brokerages have commented on CAPR. HC Wainwright increased their target price on Capricor Therapeutics from $24.00 to $60.00 and gave the company a “buy” rating in a report on Wednesday, December 3rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Capricor Therapeutics in a research report on Monday, December 29th. Roth Capital boosted their target price on shares of Capricor Therapeutics from $12.00 to $13.00 and gave the company a “buy” rating in a research note on Tuesday, November 11th. Wall Street Zen raised shares of Capricor Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, January 3rd. Finally, Alliance Global Partners reiterated a “buy” rating on shares of Capricor Therapeutics in a report on Wednesday, December 3rd.

Capricor Therapeutics Stock Performance

Shares of Capricor Therapeutics stock opened at $26.31 on Monday. Capricor Therapeutics has a one year low of $4.30 and a one year high of $40.37. The company has a market cap of $1.20 billion, a P/E ratio of -14.62 and a beta of 0.22. The firm has a fifty day moving average of $17.21 and a two-hundred day moving average of $10.84.

Capricor Therapeutics (NASDAQ:CAPR) last issued its earnings results on Monday, November 10th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.54). As a group, equities analysts predict that Capricor Therapeutics will post -1.21 earnings per share for the current year.

Institutional Investors Weigh In On Capricor Therapeutics

Hedge funds have recently modified their holdings of the stock. Farther Finance Advisors LLC purchased a new stake in Capricor Therapeutics during the 3rd quarter worth $28,000. Parkside Financial Bank & Trust acquired a new position in shares of Capricor Therapeutics during the third quarter worth about $36,000. Russell Investments Group Ltd. boosted its position in shares of Capricor Therapeutics by 122.2% in the third quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company’s stock worth $37,000 after buying an additional 2,786 shares during the period. GoalVest Advisory LLC acquired a new stake in shares of Capricor Therapeutics in the fourth quarter valued at about $59,000. Finally, Tower Research Capital LLC TRC grew its stake in shares of Capricor Therapeutics by 280.8% in the second quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company’s stock valued at $67,000 after buying an additional 4,976 shares in the last quarter. 21.68% of the stock is owned by institutional investors and hedge funds.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.